BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38091052)

  • 1. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
    Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
    Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
    Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases].
    Wang YC; DU WC; Yin CY; Gong X; Li YF
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):561-565. PubMed ID: 35644197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
    Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
    Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
    Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
    Wang BT; Dang HB; Wei YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.
    Zhen Z; Zhu J; Wang J; Lu S; Sun F; Huang J; Sun X
    Pediatr Hematol Oncol; 2020 Sep; 37(6):489-499. PubMed ID: 32364412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
    Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
    N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
    Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience.
    Cairo MS; Sposto R; Perkins SL; Meadows AT; Hoover-Regan ML; Anderson JR; Siegel SE; Lones MA; Tedeschi-Blok N; Kadin ME; Kjeldsberg CR; Wilson JF; Sanger W; Morris E; Krailo MD; Finlay JL
    Br J Haematol; 2003 Feb; 120(4):660-70. PubMed ID: 12588354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.
    Cairo MS; Sposto R; Gerrard M; Auperin A; Goldman SC; Harrison L; Pinkerton R; Raphael M; McCarthy K; Perkins SL; Patte C
    J Clin Oncol; 2012 Feb; 30(4):387-93. PubMed ID: 22215753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.
    Atra A; Imeson JD; Hobson R; Gerrard M; Hann IM; Eden OB; Carter RL; Pinkerton CR
    Br J Cancer; 2000 Apr; 82(8):1396-402. PubMed ID: 10780517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burkitt lymphoma in children: the Israeli experience.
    Eldar AH; Futerman B; Abrahami G; Attias D; Barak AB; Burstein Y; Dvir R; Gabriel H; Horovitz J; Kapelushnik J; Kaplinsky H; Miskin H; Sthoeger D; Toren A; Vilk-Revel S; Weintraub M; Yaniv I; Linn S; Arush MB
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):428-36. PubMed ID: 19648792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
    Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
    J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.